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Abstract 
Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) may be protective 
against tumours, including breast cancer. We have studied the effects of ibuprofen 
and aspirin on DNA damage in lymphocytes obtained from breast cancer patients 
and healthy female controls. Both nanoparticle (NPs) and bulk formulations were 
used in the comet and micronucleus (MN) assays. Non-toxic doses (250 ng/ml 
ibuprofen; 500 ng/ml aspirin) were tested.  Aspirin, both bulk and nano formulations, 
significantly reduced DNA damage measured with the comet and micronucleus 
assays; the nano formulation was more effective. Ibuprofen was not effective in the 
comet assay but showed a significant reduction in MN frequency, with the  nano 
formulation being more effective. NPs may have better penetration through the 
nuclear membrane relative to the bulk formulation. NSAIDs such as aspirin and 
ibuprofen may have a promising role in cancer prevention and treatment. 
  
1. Introduction  
Breast cancer (BC) is the most common cancer affecting females worldwide [1]. BC 
is more common in developed countries compared to developing countries. Overall 
survival from BC is increasing but remains poorer in developing countries [1, 2]. 
Factors in developing nations may include adaptation to Western life-styles; less BC 
screening; and poorer health-care [1]. BC arises from genetic and epigenetic 
alterations in mammary cells [3, 4].   
The effects of NSAID (ibuprofen, aspirin) use on the incidence of malignancies, 
including the most prevalent types (lung, prostate, colon, and breast cancers) have 
been studied [5, 6]. NSAID intake appears to reduce cancer risk. Daily use of 
NSAIDs, usually aspirin, was associated with risk reductions of 39% (BC), 63% 
(colon cancer), and 39% (prostate cancer). After 5 y use, NSAIDs impact became 
apparent, and the effect increased with duration of use [6]. Researchers have 
emphasized the role of NSAIDs as inhibitors of the cyclooxygenase enzymes COX-1 
and COX-2, since inflammation is believed to play a role in BC. 
The use of aspirin for prevention of BC is a relatively new subject of study [7]. 
Protection against BC was observed in some patients who regularly took aspirin, 
such as patients with cardiac disease. The reduction of BC incidence was linked to 
inhibition of COX-1 and COX-2, with the former enzyme being inhibited more 
strongly. COX inhibition blocks production of prostaglandin H2 from its precursor, 
arachidonic acid, in turn blocking production of other of prostaglandins [7, 8]. 
Inhibition of prostaglandin production inhibits their physiological roles, such as 
promotion of cell growth and angiogenesis, contributing to the antitumour effect of 
NSAIDs. Aspirin also stimulates the AMP-activated protein kinase (AMPK) signalling 
pathway, thereby inhibiting cancer cell growth.  
Prostaglandin E2 can increase expression of aromatase, which is responsible for the 
biosynthesis of oestrogen. Thus aspirin may indirectly inhibit oestrogen production 
and associated BC growth. Nevertheless, caution should be exercised in the use of 
aspirin as a single agent for BC chemoprevention, due to limited available results on 
its protective action [7, 8]. 
Harris et al (1999) compared the effects of certain NSAIDs, including ibuprofen, on 
BC patients. Regular ibuprofen use was associated with reduction of the BC rate by 
about half, and it was suggested that the drug might be useful in BC prevention [9, 
10].  
We have investigated the effects of aspirin and ibuprofen on genotoxicity, using 
lymphocytes obtained from BC patients and healthy female controls. Two different 
particle sizes were compared: nanoparticles (NPs) and bulk sizes. The comet assay 
[11-14] and micronucleus (MN) genotoxicity assays [15, 16] were used. 
Lymphocytes were selected for this study because they may reflect DNA damage 
induced by both endogenous and exogenous genotoxins, whether chemical or 
physical agents [17, 18]. 
The comet assay (single-cell gel electrophoresis assay) can measure DNA damage 
[11, 19]. It is a highly sensitive method for detection of DNA cross-links and may be 
applied to any eukaryotic cell [20, 21]. The cytokinesis block micronucleus assay 
(CBMN) is the preferred method for use with human lymphocytes, since it is 
restricted to divided binucleate cells. MN are remnants of centric chromosome 
fragments or entire chromosomes. This fragment nucleus is not incorporated in the 
daughter nucleus [15, 16]. The CBMN is commonly used to track DNA damage in 
human lymphocytes [15]. 
  
2.0 Material and Methods 
2.1. Blood sample collection 
Whole blood was collected by venepuncture after receiving informed consent from 
healthy female volunteers and BC patients. The BC samples were provided by the 
Ethical Tissue Bank using licence 12191. Bblood was collected in labelled lithium 
heparin-coated tubes. Ethical approval was granted by the University of Bradford’s 
Sub-Committee for Ethics in Research involving Human Subjects (Reference no.: 
0405/8). Control samples were also taken under IRAS/NRES application 
12/YH/0464. The Research Support and Governance Office Bradford Teaching 
Hospital NHS Foundation granted the Re DA number: 1202. Samples were diluted 
1:1 with RPMI-1640 medium and then 10% DMSO was added. The diluted blood 
samples were divided and transferred to labelled Eppendorf® tubes, which were 
tightly closed and stored at -80°C. However, blood samples were used freshly in the 
MN assay. The characteristics of the samples are shown in Tables 1a and b. 
 
  
Table 1a Healthy control individual characteristics 
Control 
sample 
No 
Age Ethnicity Smoking 
pack 
year 
Smoking 
history 
Family 
history 
Past medical 
history 
A1 34 Asian ---- No No No 
M1 40 Asian ---- No No No 
R1 34 Asian ---- No No No 
S1 30 Asian ---- No No No 
K1 44 Asian ---- No No No 
CH1 29 Asian 5 10/d BC No 
SH1 33 Asian ---- No No No 
A18 41 Asian ---- No No No 
O1 36 Asian ---- No No No 
1723 45 Caucasian ---- No No No 
4107 56 Caucasian ---- No No No 
4113 80 Caucasian ---- Ex-smoker Heart 
disease 
Osteoporosis 
4114 45 Caucasian ---- No No No 
4115 45 Caucasian ---- No No Arthritis 
4122 50 Caucasian ---- No No No 
4522 52 Caucasian ---- No No No 
4523 53 Caucasian 21 10/d-42y No Lumbar disc 
4524 60 Caucasian ---- No No No 
4526 61 Caucasian ---- No No No 
4922 53 Caucasian 16 10/d-32y No No 
 
  
Table 1b Breast cancer patient characteristics. 
BC 
sample 
No 
Age Ethnicity Smoking 
pack 
year 
Smoking 
history 
Family 
history 
Past  medical 
history 
4796 80 Asian ---- No No No 
4802 51 Caucasian 7.5 15/d No No 
4805 85 Caucasian ---- No No No 
5076 71 Caucasian ---- No No kidney transplant 
5189 41 Asian ---- No No No 
5351 70 Caucasian 10 10/d No IHD, Chol 
5357 81 Caucasian ---- No No HTN, Chol 
5363 47 Caucasian 6 20/d No No 
5364 47 Caucasian ---- No No No 
5372 32 Caucasian 2.1 7/d No N 
5375 65 Asian ---- No No HRT 
5554 36 Asian ---- No No No 
5558 46 Caucasian ---- No No No 
5572 57 Caucasian 4.5 15/d No No 
5604 58 Asian ---- No No No 
5608 50 Caucasian 6 10/d No No 
5723 60 Caucasian ---- No No No 
6003 58 Caucasian 13 20/d-13y BC No 
6010 53 Caucasian 1 10/d-2y Ovarian 
cancer 
No 
6011 55 Caucasian ---- No BC No 
  
2.2. Chemicals 
The chemicals used were: aspirin (CAS 50-78-2) Sigma Gillingham, Dorset UK, 
cytochalasin-B (CAS. 14930-96-2) Sigma-Aldrich Gillingham, Dorset UK, ethanol (CAS 
64-17-5) Sigma Gillingham, Dorset UK, ethidium bromide (CAS 1239-45-8) Sigma 
Gillingham, Dorset UK, hydrogen peroxide (CAS 7722-84-1) Sigma UK, mitomycin C 
(CAS 50-07-7) Sigma-Aldrich Gillingham, Dorset UK, ethylenediamine tetraacetic acid, 
disodium dihydrate (Na 2 EDTA·2H 2 O) (CAS 6381-92-6) Sigma Gillingham, Dorset 
UK, NaCl (CAS 7647-14-5) Sigma Gillingham, Dorset UK, and phosphate-buffered 
saline (PBS) Sigma Gillingham, Dorset UK. Roswell Park Memorial Institute medium 
(RPMI-1640), trition X-100 (CAS 9002-93-1) Sigma-Aldrich Gillingham, Dorset UK, 
trizma base (CAS 77-86-1) Sigma Gillingham, Dorset UK, trypan blue (CAS 72-57-1) 
were purchased from Sigma-Aldrich, Gillingham, Dorset UK. Dimethyl sulfoxide 
(DMSO) (CAS 67-68-5) and NaOH (CAS 1310-73-2) were purchased from BDH, 
Poole Dorset UK. Fetal bovine serum and phytohaemagglutinin liquid (CAS 9008-97-
3) were purchased from GIBCO Invitrogen Paisley UK. Ibuprofen USP (CAS 15687-
27-1) was purchased from Sigma-Aldrich, Gillingham, Dorset UK. Low-melting-point 
agarose (LMP) (CAS 39346-81-1), normal-melting-point agarose (NMP) and (CAS 
9012-36-6) were from Invitrogen, Paisley UK. Lymphoprep (CAS 66720-17-0) was 
from Axis-Shield, Norway. 
2.3. Preparation of nanoparticles.   
Aspirin and Ibuprofen were suspended (3% and 4% (w/w), respectively) with solid 
loads in special suspension medium, which was prepared from melting 
polyvinylpyrrolidone K-30 (0.5% w/w), hydroxypropyl methylcellulose (HPMC) (0.5% 
w/w), and sodium lauryl sulphate (0.1% w/w) in deionised water. A Lena nanoceutics 
technology DM-100 machine was used to mill the suspensions. Yttrium, 0.2 mm, 150 
ml, was used to mill a 250 ml portion of each suspension in the presence of 
stabilised zirconium beads (Glen Mills, USA). Recycling the suspension in the milling 
machine took 60 min, before discharge and transfer to an impervious glass bottle. 
The suspensions were stored at 4°C.   
2.4. Comet assay 
2.4.1. Cell treatment 
Twenty stored blood samples each from healthy volunteers and BC patients were 
allowed to thaw at room temperature.Bblood suspension, 100 μl,  was added to 
RPMI-1640 medium, 890 μl, in Eppendorf® tubes, which contained negative control 
solvent (NC), 10 μl, positive control (PC) (50 μM H2O2), and the test articles:  
ibuprofen (250 µg/ml) and aspirin (500 µg/ml), in nano and bulk formulations. The 
alkaline comet assay (pH >13) was performed as described previously [11-14]. 
2.4.2. Staining and comet scoring 
Ethidium bromide (20 μg/ml) stain was used for DNA staining; a 60 μl aliquot of dye 
was added on the top of each slide and covered with a cover slip. The slides were 
scored under a fluorescence microscope connected to image analysis software 
(Andor, Belfast, UK). A 20 x magnification lens was used. 100 cells were selected 
randomly from each slide for analysis. 
2.5. Micronucleus assay (CBMN) 
Fresh blood samples from each of five healthy volunteers and five BC patients were 
used. Before starting the culture, T25 cm³ flasks containing 4.5 ml frozen prepared 
medium were placed in a 37°C incubator (5% CO2) for 30 min. Sterile materials and 
solutions were used when performing lymphocyte 72 h cultures. The protocol was as 
described by Fenech [15], [16]. 
 Various cytological scoring parameters were used, including cell mitotic status, 
mononucleated cells (monoNC), binucleated cells (BiNC), multinucleated cells 
(MultiNC), nuclear division index (NDI), and chromosomal damage/instability 
parameters in the form of nucleoplasmic bridges (NPBs) and nuclear buds (NBUDs) 
in lymphocytes. MNi, NBPs, and NBUDs were scored in BiNC up to 500 cells. 500 
other cells were scored to calculate the percentages of each type of cells: monoNC, 
BiNC, and MultiNC. After scoring proportions, three cell types were used to calculate 
the NDI, to measure the rate of mitotic division and cytostatic effects [15]. 
2.6. Aspirin and ibuprofen concentrations 
Two different sizes of ibuprofen and aspirin were used (NPs and bulk), using the 
same concentrations for both sizes. The concentration were 250 µg/ml Ibuprofen and 
500 µg/ml aspirin. These concentrations were selected according to the differences 
in properties of the two drugs and did not cause cytotoxicity/ apoptosis (data not 
shown).  
2.7. Cell viability  
Cell viability was evaluated for lymphocytes after 30 min treatment with ibuprofen or 
aspirin. Cells were centrifuged in a micro-centrifuge at 450 x g for 5 min at room 
temperature. Then, 0.4% trypan blue solution was mixed with the cells, 1:1, and 100 
cells were recorded. 
2.8. Statistical analysis  
Data were analysed using Graphpad and SPSS 18.0. (one-way ANOVA) and p ≤ 
0.05 was considered significant. 
 
 
3. Results 
The percentages of smokers were 11% (healthy controls) and 35% BC patients. We 
believe that neither smoking status nor ethnicity confounded the responses, in view 
of the uniformity of the data; the t-test showed no significant differences between  
smoking status and ethnicity in the control and patient groups.  
Figures 1a and b show the comet assay concentration responses of the nano and 
bulk formulations of ibuprofen on lymphocyte DNA from BC patients and healthy 
controls, using Olive tail moment and % tail DNA parameters. Ibuprofen reduced 
lymphocyte DNA damage among BC patients but the reduction was not statistically 
significant.  
Figures 2a and b show the corresponding data sets for aspirin. Aspirin significantly 
reduced lymphocyte DNA damage for BC patients. However, healthy control 
samples showed weak and non-significant damage increases, compared to 
untreated cells.  
Neither aspirin nor ibuprofen showed significant differences between the bulk and 
nano forms.   
Tables 2a and b show the CBMN assay results following exposure to ibuprofen and 
aspirin, NPs and bulk, with respect to the cytological scoring parameters for  
lymphocytes from five female volunteers and five BC patients. In general, MN 
frequencies were reduced by both ibuprofen and aspirin. 
 
4. Discussion 
Various studies [5, 6] have suggested that NSAIDs can prevent tumours, including 
BC, and this protective effect may be mediated by pathways involving inhibition of 
COX1 and COX2 and the expression of tumour suppressor genes such as p53 [22, 
23]. Ibuprofen and aspirin are the most commonly used NSAIDs [5, 6, 24]. In this 
work, ibuprofen and aspiri, NPs and bulk, were studied for their protective effect on 
DNA damage in BC patients, using lymphocytes as surrogate cells. 
Generally, both aspirin and ibuprofen caused a reduction in DNA damage and MN 
formation in lymphocytes from BC patients. Aspirin, both bulk and nano sizes, gave a 
significant reduction in DNA damage in both the comet and MN assays. Ibuprofen, in 
contrast, showed a significant reduction with the MN assay, with both NPs (P≤0.001) 
and bulk forms (P≤0.01), but any effect in the comet assay was weak or insignificant. 
Noote that the incubation times for the comet assay (30 min) and MN assay (72 h) 
are very different, which may explain the different results. This explanation is 
consistent with the fact that NPs have better penetration through nuclear 
membranes, due to their smaller sizes compared to the bulk form.  
Ibuprofen genotoxicity has been debated. Genotoxicity of ibuprofen in 
Salmonella strains was inconclusive [25] . Philipose et al [25], on the other hand, 
demonstrated genotoxicity of ibuprofen in mice, namely the induction of sister 
chromatid exchange. Ghosh et al [26] found that ibuprofen had no genotoxic effect 
over a short period (two weeks) in human peripheral whole blood cells and isolated 
lymphocytes. Tripathi et al [27] conducted a similar study to investigate ibuprofen 
genotoxicity in mouse bone marrow cells. They concluded that ibuprofen has a 
genotoxic effect and that this effect was more pronounced at 40 and 60 mg/kg b.w. 
doses  than at 10 and 20. 
Aspirin is not genoitoxic. A protective effect was observed in mice when aspirin 
(doses 0.5, 5, or 50 mg/kg b.w.) was combined with the genotoxic anticancer agent 
mitomycin (MMC, 2 mg/kg b.w). Aspirin reduced the genotoxocity of MMC in the liver 
and spleen, in a dose-dependent manner [28, 29]. These findings are in accord with 
the outcomes of our study. Niikawa et al. [28] suggested that aspirin many act by 
scavenging reactive oxygen species. 
Inhibition of cyclooxygenase is the mechanism most commonly proposed for 
aspirin’s protective activity. COX enzyme has an important function in the synthesis 
of prostaglandin endoperoxides. Prostanoids, including prostaglandins, are essential 
biological mediators and serve various biological roles. Three forms of COX are 
known: COX1, COX2, and COX3. Aspirin and ibuprofen can block both COX1 and 
COX2; their inhibition effects are greater on COX1 [30]. Prostaglandins have roles  in 
cell division, migration, angiogenesis, and apoptosis [31]. In addition, many 
preclinical studies have found that the pro-inflammatory compound prostaglandin E2 
(PGE2) catalyses oestrogen production by increasing expression of aromatase. 
Aromatase, a cytochrome P450 enzyme, catlyzes production of oestrogen from 
androgens. COX enzymes stimulate PGE2 production, CYP19 transcription, and 
aromatase activity. These findings are consistent with the observation of a positive 
correlation between COX enzyme levels and CYP19 expression in human breast 
carcinoma [32]. The breast cancer prevention effects of aspirin and ibuprofen may 
be linked to inhibition of prostaglandin production and, ultimately, oestrogen 
production and mammary cell proliferation [7]. 
5. Conclusions 
Ibuprofen and aspirin, both bulk and NP forms, reduced comet assay DNA 
damage in lymphocytes from BC patients but not in healthy volunteers. The MN 
assay data showed a decrease in MN frequency, which followed a similar pattern to 
the results for the comet assay. In both assays, aspirin was more effective than 
ibuprofen. NPs of both agents were more effective than the bulk formulations. Our 
results are consistent with the hypothesis that NSAID have a promising role in BC 
prevention and treatment. 
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Table 2a Cytological scoring parameters in lymphocytes from five healthy females  
following exposure to ibuprofen and aspirin (NPs and bulk).  
 
 
 
Conc = concentration 
NC = negative control 
PC = positive control 
NPs = nanoparticles 
NDI = the nuclear division index  
BiNC = Binucleated cells, % BiNC, is % expressed out of all types of 500 cells scored.   
MultiNC = Multinucleated cells % MultiNC, is % expressed out of all types of 500 cells 
scored.  
MNi = Micronuclei score/500 cells each of BiNC  
NPBs = nucleoplasmic bridges 
NBUDs = nuclear buds 
 All groups are  compared to the negative control (NC), using * p = < 0.05, ** p = < 0.01, *** p 
= < 0.001 for significance and ns (ns) = not significant.  
 
 
 
 
  
Table 2b Cytological scoring parameters in lymphocytes from five BC patients 
following exposure to ibuprofen and aspirin (NPs and bulk). 
 
 
Conc = concentration 
NC = negative control 
PC = positive control 
NPs = nanoparticles 
NDI = the nuclear division index  
BiNC = Binucleated cells, % BiNC, is % expressed out of all types of 500 cells scored.   
MultiNC = Multinucleated cells % MultiNC, is % expressed out of all types of 500 cells 
scored.  
MNi = Micronuclei score/500 cells each of BiNC  
NPBs = nucleoplasmic bridges 
NBUDs = nuclear buds 
 All groups are  compared to the negative control (NC), using * p = < 0.05, ** p = < 0.01, *** p 
= < 0.001 for significance  and ns (ns) = not significant. 
 
 
 
 
  
Figure legends  
Figure 1a Comparison of ibuprofen concentration responses, ±SE, and significance 
levels in DNA from lymphocytes DNA from healthy volunteers and BC patients using 
Olive tail moment. N=20 
Figure 1b Comparison of ibuprofen concentration response, ±SE, and significance 
on lymphocytes DNA from healthy volunteers and BC patients; % tail DNA. N=20 
Figure 2a Comparison of the aspirin concentration response, ±SE, and significance 
level in DNA from lymphocytes DNA from healthy volunteers and BC patients; Olive 
tail moment. N=20 
Figure 2b Comparison of the aspirin dose response, ±SE, and significance on 
lymphocyte DNA from healthy volunteers and BC patients; % tail DNA. N=20 
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